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Potential links between metabolic derangements and adipose tissue (AT) inﬂammation in patients with chronic obstructive
pulmonary disease (COPD) are unexplored. We investigated AT expressions of interleukin (IL)-6, tumor necrosis factor (TNF)-α,
CD68(macrophagecellsurfacereceptor),caspase-3,andBax,andtheirrelationshipstothemetabolicphenotypeinninecachectic,
12 normal-weight, 12 overweight, and 11 obese patients with COPD (age 62.3 ± 7.2 years). With increasing body mass index,
increases in AT expressions of IL-6, TNF-α, and CD68 were observed (P<. 001; P = .005; P<. 001, resp.), in association
with reduced insulin sensitivity (P<. 001). No diﬀerences were observed between cachectic and normal-weight patients in AT
expressions of inﬂammatory or proapoptotic markers. Adipose tissue CD68 and TNF-α expressions predicted insulin sensitivity
independently of known confounders (P = .005; P = .025; R2 = 0.840). Our results suggest that AT inﬂammation in obese
COPD patients relates to insulin resistance. Cachectic patients remain insulin sensitive, with no AT upregulation of inﬂammatory
or proapoptotic markers.
1.Introduction
Low-grade systemic inﬂammation is considered a hallmark
of COPD and a mechanism potentially linking COPD to
increasedrateofsystemicmanifestationsofthisdisease.Both
cachexia and obesity with/without the metabolic syndrome
(MetS) represent two poles of metabolic abnormalities that
are prevalent in patients with COPD and are related to
adverse clinical outcomes [1]. Multiple studies demonstrated
relationships between systemic inﬂammation, reﬂected by
increasedinﬂammatorymediatorsinthesystemiccirculation
and metabolic derangements in COPD patients [2–8].
Nevertheless, to our best knowledge no data were published
on adipose tissue inﬂammation in either obese or cachectic
patients with this disease. This contrasts with a wealth
of studies that have demonstrated close links between
inﬂammatory processes within the adipose tissue, metabolic
impairment, and either obesity [9, 10]o rc ac h e x i a[ 11, 12]i n
disorders other than COPD.
White adipose tissue is currently viewed as a highly dy-
namic endocrine organ that, apart from its metabolic func-
tion, releases a wide variety of products with both systemic
and local eﬀects [13, 14]. The inﬁltration of adipose tissue
with macrophages aggravates local production of inﬂam-
matory cytokines such as interleukin (IL)-6 and tumor
necrosis factor-alpha (TNF-α) that, in turn, initiate a nega-
tive set of events on adipocyte function including impaired
lipolysis and reduced insulin responsiveness [15]. The pro-
duction of IL-6 and TNF-α is increased in adipose tissue of
obese individuals [9, 10], and adipose tissue inﬂammation is2 Mediators of Inﬂammation
considered to represent an important pathogenetic factor
in the development of obesity-related complications such
as insulin resistance [16]. Of note, in patients with COPD,
increases in IL-6 and TNF-α in the systemic circulation
have been linked to obesity [2] and insulin resistance [3];
nevertheless, no reports analyzed the role of inﬂammation
within the adipose tissue itself in metabolic derangements in
such patients.
Among patients with COPD and normal body mass
index (BMI), approximately 10% suﬀer from selective wast-
i n go ff a t - f r e em a s s( F F M )[ 17, 18]. Nevertheless, in most
cachectic patients with advanced COPD, parallel loss of
both muscle and fat mass occurs [5, 19]. Although several
studies suggested that there is a link between COPD-related
wasting and systemic inﬂammation [6, 20], mechanisms and
eﬀects of this inﬂammatory response are not clear. Studies
in adipocyte cell lines and in animal models suggest that
inﬂammatory cytokines such as TNF-α may reduce the size
of adipose tissue depots by several mechanisms, including
acceleration of apoptosis [9]. Protein encoded by tumor
necrosis factor receptor superfamily 1A (TNFRSF1A) gene
is one of the major receptors in TNF-α signaling pathway
that activates nuclear factor kappa-B, mediates apoptosis,
and acts as a regulator of inﬂammation [21]. Therefore, a
question arises whether COPD-related cachexia is associated
with local adipose tissue inﬂammation, and, if so, whether
adipose tissue inﬂammation relates to the activation of
proapoptotic processes with subsequent loss of fat mass.
Adipose tissue expressions of proinﬂammatory and
proapoptotic markers, and their potential links to metabolic
derangements among either cachectic or obese patients with
COPD are unexplored. Therefore, in the present study we
investigated expressions of proinﬂammatory IL-6, TNF-α,
TNFRSF1A, CD68 (macrophage cell surface receptor), and
of proapoptotic caspase-3 (CASP3) and Bax, and their rela-
tionshipstothemetabolicphenotypeinpatientswithCOPD.
2. Methods
2.1. Subjects. Patients with diagnosis of COPD according
to the American Thoracic Society/European Respiratory
Society guidelines [22], free from exacerbation for ≥8w e e k s ,
wererecruitedfromtwoout-patientclinicsaﬃliatedwiththe
university hospital setting. The MetS was diagnosed accord-
ingtotherecentInternationalDiabetesFederationdeﬁnition
[23]. Patients with BMI < 20.0kg·m−2 and fat-free mass
index <17.0kg·m−2 (males)or<14.0kg·m−2 (females)were
considered cachectic [24, 25]. Exclusion criteria were use
of systemic corticosteroids, treatment with long-term home
oxygen therapy, respiratory disorders other than COPD,
known diabetes or other metabolic or endocrine disorder,
chronic autoimmune, hepatic or renal disease, malignancy,
overt cardiac failure, blood coagulation disorder, or therapy
with warfarin. Dyspnea severity was evaluated using the
ModiﬁedMedicalResearchCouncil(MMRC)scale[26].The
distance traveled within 6 minutes (6MWD) was recorded
without use of supplemental oxygen. Information regarding
exacerbations in the preceding year, and medication use was
retrieved from patients’ charts of the referring physicians.
This study is a part of an ongoing study on the metabolic
consequences of COPD (MOPD) and had approval of the
institutional Ethics Committee. All subjects gave written
consent to the study.
2.2. Pulmonary Function Tests. Pulmonary function tests
were evaluated with the use of bodyplethysmography (Gan-
shorn, Germany). All pulmonary function testing was
performed according to the European Respiratory Society
standards with the patients in a sitting position by the same
technician in order to ensure consistency of the technique.
Three technically acceptable measurements were performed
in each patient, and the highest value was included in the
analyses. COPD severity was evaluated on the basis of GOLD
recommendations [27].
2.3. Body Composition. Body composition was obtained
using Dual Energy X-Ray Absorptiometry (DEXA) with fan-
beam technology (Lunar Prodigy, GE Healthcare). Body
weight, fat free mass, and fat mass were adjusted for height
squaredasthefatfreemassandfatmassindices(BMI,FFMI,
FMI, resp.).
2.4. Insulin Sensitivity. To determine insulin sensitivity, we
used a 2-hour hyperinsulinemic-euglycemic clamp with a
primed-continuousinsulininfusionrateof1mIU·min−1 per
kg body weight and a variable 20% glucose infusion adjusted
every5mintomaintainplasmaglucosewithin0.5mmol·L−1
(±10%) of target glucose level (5.0mmol·L−1)[ 28]. The
mean amount of glucose infused during the last 40 minutes
was used to calculate the rate of whole-body glucose uptake
(M value). Serum insulin levels (I)w e r em e a s u r e da t1 5m i n
intervals. Insulin sensitivity is expressed as the M/I ratio
averaged over the ﬁnal 40min of the clamp.
2.5. Biochemical Analyses. In all patients, peripheral venous
blood samples from the antecubital vein were collected
between 7.00 and 8.00AM after 10 hour fast. Serum insulin
was determined with electrochemiluminescence immunoas-
say kits (Elecsys) on Roche Elecsys 1010/2010 and modular
analytics E170 immunoassay analyzers (Roche Diagnostics
GmbH, Mannheim, Germany); plasma glucose was mea-
sured by the glucose oxidase method on a Beckman autoana-
lyzer. High-sensitivity serum C-reactive protein (CRP) levels
were assessed by immunoturbidimetric method (Randox,
UK). The analytical sensitivity of this CRP assay is of
0.1mg/L. Serum TNF-α and IL-6 levels were measured using
commerciallyavailableenzyme-linkedimmunosorbentassay
kits (Beckmann-Coulter Immunotech). Serum free fatty
acids (FFA) levels were determined using a colorimetric
assay (Randox, UK). At the time of venous blood samples
collection, arterial blood sample was obtained by puncture
of radial artery for blood gas analysis.
2.6.IL-6,TNF-α,TNFRSF1A,CD68,CASP3,andBaxExpres-
sions. Abdominal subcutaneous adipose tissue was taken by
aspiration with a bioptic needle (Medin, Czech Republic)Mediators of Inﬂammation 3
under local intracutaneous anesthesia with 1% mesocain
after an overnight fast. The samples were quickly washed
in saline to eliminate blood and other connective tissue,
immediately frozen in liquid nitrogen, and stored at −80◦C
until analysis.Total RNAwasisolated using theRNeasyLipid
Tissue mini kit (Qiagen, Germany); DNAse treatment was
included. RNA quantity, purity, and integrity were deter-
mined with the microﬂuidic chips Experion RNA analysis
kit (BioRad) as well as with nanophotometer (IMPLEN,
Germany). Reverse transcription was performed with aid of
HighCapacityRNAtocDNAkit(AppliedBiosystems,USA).
Gene expression was measured in duplicates with aid of the
real-time PCR (RotorGene 2000 real-time cycler, Corbett
Research, Australia) using the TaqMan Gene Expression
Assays (Applied Biosystems, USA). Comparative quantiﬁca-
tion method (ΔΔCt) was used to calculate the relative gene
expression [29].
Adipocyte diameter was assessed histomorphologically
on the 5μm thick sections of adipose tissue stained with
Hematoxylin & Eosin. The cell diameter was determined
using the ImageJ freeware (UTHSCA, USA). Average diame-
ter of at least 100 cells from each adipose tissue section was
calculated.
2.7. Statistical Analyses. Statistical analyses were performed
using SPSS software version 14.0 (SPSS Inc., USA). Power
calculations were performed based on published IL-6 mRNA
expressions in human subcutaneous adipose tissue [30]. For
standard deviation of 2.6 in four studied groups, a power
calculation indicated that we would need a total sample size
of at least 38 patients to detect a diﬀerence of 2 ΔΔCt in IL-6
mRNA expression with a power of 80% at a 0.05 signiﬁcance
level.
The Kolmogorov-Smirnov test of normality was applied.
Diﬀerences between groups in normally distributed vari-
ables were tested by analysis of variance (ANOVA) with
Bonferroni’s post hoc test, and in nonnormally distributed
variables by ANOVA on ranks with Dunn’s post hoc test.
Fisher exact test was used to compare the proportion of
categoric variables between groups. To assess the relation-
ships between selected variables, linear regression analysis
was used. Because the distributions of mRNA expressions
and serum cytokine concentrations were all skewed, we used
the log-transformed values of these variables in regression
analyses. In the multivariate analyses, multiple linear regres-
sion models were used with insulin resistance (M/I value)
as the dependent variable, and age, gender, forced expiratory
volume in 1 second (FEV1), BMI, and log transformed
adipose tissue mRNA expressions as independent variables.
Continuous variables are shown as means ± SD, nonnor-
mally distributed variables as median (interquartile range).
3. Results
3.1. Patients. Forty-four patients with COPD (38 men and
6 women) were enrolled. They were generally late middle-
aged (mean age 62.3 ± 7.2y e a r s )w i t ham e a n3 3 .8 ±
25.9 pack years history of smoking. Patients were divided
into four groups: the ﬁrst was formed by nine cachectic
patients (BMI < 20.0kg·m−2), the second by 12 normal-
weight (BMI 20.0–24.9kg·m−2), the third by 12 overweight
(BMI 25.0–29.9kg·m−2), and the fourth by 11 obese (BMI
≥ 30.0kg·m−2) patients. Table 1 displays demographic
data, body composition parameters, pulmonary functions,
and circulatory inﬂammatory markers in the four studied
groups. No diﬀerences were observed in the demographic
characteristics among the groups. Cachectic patients had
signiﬁcantly lower, whereas obese patients had signiﬁcantly
higher FFMI and FMI compared to normal-weight patients
(P<. 05 for all comparisons).
With increases in BMI, FEV1,a n dF E V 1/forced vital
capacity (FVC) ratio and diﬀusion capacity for carbon
monoxide signiﬁcantly increased (P = .007, P = .019, P<
.001, resp.), while residual volume (RV), total lung capacity
(TLC), and RV/TLC ratio signiﬁcantly decreased (P = .007,
P = .026, P = .029, resp.) (Table 1). No diﬀerences were
observed between the four groups in serum levels of IL-6,
TNF-α, and high sensitivity CRP. None of the patients in the
cachectic group fulﬁlled the criteria for the MetS, whereas
these criteria were met by 2 of 12 normal-weight, 5 of 12
overweight, and 10 of 11 obese patients. Table 2 displays
parameters of the respective components deﬁning MetS in
the studied groups.
3.2. Insulin Sensitivity and Free Fatty Acids. From cachectic
to normal-weight, overweight, and obese patients with
COPD, there were signiﬁcant reductions in insulin sensi-
tivity, in association with higher FFA at the steady state of
euglycemic hyperinsulinemic clamp (P<. 001; P = .004,
resp.) (Table 3).
3.3. Adipose Tissue Expression of IL-6, TNF-α, TNFRSF1A,
and CD68. Signiﬁcant increases in the adipose tissue mRNA
expressions of IL-6, TNF-α, TNFRSF1A, and CD68 were
observed from cachectic to normal-weight, overweight, and
obese COPD patients (ANOVA for trend, P<. 001; P =
.005; P = .011, P = .011, resp.), in association with
increases in adipocyte diameter (P<. 001) (Table 4).
Histomorphological picture of subcutaneous adipose tissue
derived from a cachectic and overweight participant in
this study is illustrated in Figure 1. Compared to normal-
weight patients, obese subjects had signiﬁcantly higher
adipose tissue expressions of CD68 and TNF-α expressions.
CD68 expression correlated directly with IL-6, TNF-α,a n d
TNFRSF1A expressions (r = 0.493, P<. 001; r = 0.421,
P = .005; r = 0.509, P<. 001, resp.). Importantly, no
diﬀerences were observed between cachectic and normal-
weight groups in any of the studied adipose tissue mRNA
expressions. Also, no relationships were observed between
adipose tissue expressions of IL-6, TNF-α,o rC D 6 8a n d
concentrations of inﬂammatory mediators in the systemic
circulation, FEV1,o rP a O 2.
Adipose tissue expressions of IL-6, TNF-α, and CD68
correlated all directly with BMI and adipocyte diameter,
and inversely with insulin sensitivity (Table 5). To further4 Mediators of Inﬂammation
Table 1: Patient characteristics.
Variable Entire cohort Group P value
Cachectic Normal weight Overweight Obese
Patients, no. (%) 44 (100) 9 (20.5) 12 (27.3) 12 (27.3) 11 (25) .867
Age, yr 62.3 ±7.26 1 .4 ±8.26 2 .8 ±5.96 4 .3 ±7.06 0 .2 ±8.0 .580
Males, no. (%) 38 (86.3) 9 (100) 10 (83.3) 10 (83.3) 9 (81.8) .615
Smokers, no. (%) 17 (38.6) 4 (44.4) 7 (58.3) 2 (16.7) 4 (36.4) .207
Packyears, yr 33.8 ±25.94 0 .7 ±15.73 8 .8 ±25.73 7 .6 ±35.21 9 .2 ± 15.4 .232
MMRC dyspnea scale 2.0 (1.0-2.0) 2.0 (2.0-2.0) 1.0 (1.0-2.0) 2.0 (1.0-2.0) 2.0 (1.0-2.0) .228
6MWD, m 363.8 ±89.8 296.1 ±86.4 388.4 ±93.0 385.2 ±73.7 365.2 ±91.3 .105
BMI, kg·m−2 26.5 ±7.11 8 .3 ±0.8† 22.9 ±1.42 7 .7 ±1.4∗† 35.9 ±5.6∗† <.001
FFMI, kg·m−2 18.3 ±2.51 6 .1 ±0.81 7 .4 ±1.41 8 .2 ±1.5∗ 21.2 ±2.6∗†‡ <.001
FMI, kg·m−2 8.2 ±5.24 .7 ±1.3† 6.2 ±1.48 .9 ±1.5∗ 14.1 ±5.3∗†‡ <.001
Trunk FM, % 30.5 ±14.31 0 .5 ±7.62 5 .0 ±8.4∗ 39.6 ±3.3∗† 44.3 ±5.0∗† <.001
Trunk FM, kg 14.2 (6.3–17.7) 1.3 (1.2–5.1) 9.5 (5.4–10.6) 15.9 (15.5–16.9)∗ 21.4 (20.7–27.6)∗† <.001
Limbs FM, % 25.0 ±12.91 1 .4 ±6.21 9 .0 ±6.32 9 .8 ±9.8∗† 38.2 ±9.8∗† <.001
Limbs FM, kg 5.0 (3.2–7.7) 1.4 (0.9–2.6) 3.4 (3.0–3.8) 5.9 (5.5–6.9)∗ 9.4 (7.7–14.0)∗† <.001
FEV1,L 1 .58 ±0.70 1.1 ±0.91 .5 ±0.51 .9 ±0.71 .7 ± 0.6 .084
FEV1,%p r e d 5 4 .0 ±22.93 3 .8 ±19.85 1 .4 ±16.86 5 .7 ±25.0∗ 60.5 ±19.0∗ .007
FEV1/FVC ratio 50.5 ±16.73 8 .7 ±15.24 6 .5 ±13.05 7 .0 ±19.25 8 .6 ±13.2∗ .019
RV, L 4.13 ±1.39 5.3 ±1.44 .4 ±1.13 .6 ±1.3∗ 3.4 ±1.0∗ .007
TLC, L 7.29 ±1.50 8.1 ±1.17 .8 ±1.46 .8 ±1.66 .5 ± 1.3 .026
RV/TLC ratio 55.6 ±10.66 4 .3 ±13.75 5 .4 ±7.45 1 .4 ±8.6∗ 52.5 ±9.5 .029
DLCO,%p r e d 7 2 .3 ±30.93 4 .2 ±24.36 7 .1 ±15.18 7 .1 ±37.2∗ 92.0 ±7.6∗ <.001
PaO2,m mH g 6 9 .0 ±13.55 8 .7 ±19.56 9 .8 ±8.37 5 .2 ±14.3∗ 68.9 ±7.5 .048
PaCO2,m mH g 3 8 .3 ±6.83 9 .8 ±8.03 5 .7 ±3.93 8 .5 ±7.13 8 .9 ±7.2 .495
Leukocytes, ×109·L−1 7.2 ±1.77 .1 ±2.57 .0 ±1.77 .5 ±1.17 .2 ± 1.7 .921
Neutrophils, ×109·L−1 4.2 ±1.34 .4 ±2.04 .1 ±1.54 .5 ±0.73 .9 ± 0.9 .738
IL-6, pg·mL−1# 3.7 (2.9–5.5) 4.3 (3.2–5.2) 2.9 (2.0–3.8) 3.8 (3.0–5.8) 4.4 (3.0–8.6) .352
TNF-α,p g ·mL−1# 13.4 (10.6–17.5) 9.8 (8.6–14.1) 13.1 (11.0–18.1) 13.9 (11.3–20.1) 15.2 (11.3–17.3) .214
hsCRP, mg·L−1# 3.1 (1.0–7.8) 3.5 (0.8–7.4) 1.4 (0.9–7.2) 2.7 (1.1–12.0) 3.6 (1.2–4.6) .932
∗P<. 05 versus cachectic group.
†P<. 05 versus normal-weight group.
‡P<. 05 versus overweight group.
Values are given as the mean ± SD, unless otherwise indicated.
#Values are given as median (interquartile range).
MMRC: The Modiﬁed Medical Research Council Dyspnea Scale; 6MWD: 6-minute walking distance; BMI: body mass index; FFMI: fat-free mass index; FMI:
fat mass index; FM: fat mass; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity; DLCO:
carbon monoxide diﬀusing capacity; PaO2: arterial oxygen partial pressure; PaCO2: arterial carbon dioxide partial pressure; IL-6: interleukin 6; TNF-α:t u m o r
necrosis factor alpha; hsCRP: high sensitivity C-reactive protein.
Table 2: Characteristics of the respective components of the metabolic syndrome in COPD patients.
Group P value
Cachectic Normal weight Overweight Obese
Central obesity∗ 0 (0) 6 (50.0) 12 (100) 11 (100) <.001
Raised blood pressure∗ 2 (22.2) 4 (12.5) 8 (66.6) 11 (100) .001
Raised triglycerides∗ 0 (0) 1 (8.3) 1 (8.3) 7 (63.6) <.001
Reduced HDL cholesterol∗ 0 (0) 1 (8.3) 0 (0) 3 (27.3) .089
Raised fasting plasma glucose∗ 0 (0) 5 (41.6) 4 (33.3) 8 (72.7) .010
Values are given as No (%).
∗Central obesity: waist circumference > 94cm (men) or >80cm (women); raised blood pressure: systolic BP ≥ 130mmHg or diastolic BP ≥ 85mmHg, or
treatment of previously diagnosed hypertension; raised triglycerides: >150mg·dL−1 or speciﬁc treatment; reduced HDL cholesterol < 40mg·dL−1 (men) or
<50mg·dL−1 (women), or speciﬁc treatment; raised fasting plasma glucose > 100mg·dL−1 or speciﬁc treatment.
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Table 3: Insulin sensitivity determined by euglycemic hyperinsulinemic clamp and insulin-induced serum-free fatty acids in patients with
COPD.
Variable Entire group Group P value
Cachectic Normal weight Overweight Obese
M,m g ·kg−1·min−1 5.00 ±2.74 7.48 ±2.22 6.42 ±2.65 3.81 ±1.84∗† 2.71 ±1.20∗† <.001
M/I ×100, mg·kg−1·min−1 ·μU−1·mL 6.72 ±4.50 11.65 ±3.52 9.01 ±3.65 4.76 ±2.62∗† 2.33 ±1.01∗†‡ <.001
FFA, mmol·L−1 0.11 ±0.05 0.07 ±0.03 0.09 ±0.04 0.12 ±0.06 0.14 ±0.05∗† .004
∗P<. 05 versus cachectic group.
†P<. 05 versus normal-weight group.
‡P<. 05 versus overweight group.
M:g l u c o s eu p t a k e ;M/I: insulin sensitivity—glucose uptake to insulinemia ratio; FFA: free fatty acids.
strengthen analyses of these data and to eliminate the poten-
tial impact of cachectic patients on these relationships,
we performed regression analyses in a subgroup of COPD
patients after exclusion of those suﬀering from cachexia.
These analyses indicated that even when cachectic patients
were excluded, relationships remained signiﬁcant between
insulin sensitivity and CD68, IL-6, and TNF-α expressions
(r =− 0.563, P<. 001; r =− 0.473; P = .004; r =− 0.459,
P = .005, resp.). CD68 and TNF-α expressions remained
signiﬁcantly associated with BMI (r = 0.498, P = .002;
r = 0.438, P = .007, resp.), whereas the relationship between
IL-6 expression and BMI became nonsigniﬁcant (r = 0.310,
P = .066).
In multiple linear regression analysis with insulin sen-
sitivity (M/I value) as the dependent variable, and age,
gender, BMI, FEV1, log CD68, log TNF-α, and log IL-6
as independent variables, four variables were independent
predictors of insulin sensitivity: age (P<. 001), BMI (P<
.001), and log transformed adipose tissue CD68, and TNF-α
expressions (P = .005, P = .025, resp.; R2 = 0.840).
3.4. Adipose Tissue Expression of CASP3 and Bax. Adipose
tissue expressions of proapoptotic CASP3 and Bax did not
diﬀer among cachectic, normal-weight, overweight, and
obese patients with COPD (Table 4), and no relationships
between insulin sensitivity and CASP3 or Bax expressions
were observed (r = 0.162, P = .413; r = 0.122, P = .446,
resp.). In addition, inﬂammatory cytokine expressions were
not related to those of either CASP3 or Bax (Table 5).
4. Discussion
The present study provides several novel observations on
the links between adiposity, adipose tissue inﬂammation,
and insulin resistance in patients with COPD. Our data
demonstrate that obesity is linked to increased adipose tissue
expressions of CD68 and TNF-α, and that both, CD68 and
TNF-α expressions predict insulin sensitivity independently
of known confounders. Cachectic patients were not insulin
resistant, and neither upregulation of proinﬂammatory
CD68, TNF-α, or IL-6, nor increases in proapoptotic CASP3
or Bax expressions were observed in adipose tissue of such
subjects.
Obesity has emerged as an important risk factor for
respiratory disorders [31] that, in association with other
components of the MetS, may represent an underlying
mechanism contributing to increased cardiovascular risk in
COPD. The presence of three or more components of the
MetS was demonstrated in almost 50% of COPD patients
[32]. In the large-scale epidemiological study in 121,965
participants in France, three factors were inversely related
to lung function: atherogenic dyslipidemia (low high-density
lipoprotein cholesterol, high triglycerides), “glucose-blood
pressure”factor(highfasting glycemia,highblood pressure),
and abdominal obesity (large waist circumference) [33].
Other studies also demonstrated high prevalence of arterial
hypertension among patients with COPD: Marquis et al.
[32] reported raised blood pressure in 82%, and Watz et al.
[34] in up to 77% of patients with this disorder. Of note,
hypertension was highly prevalent across all GOLD stages
of COPD severity, and pulmonary function was not related
to increases in blood pressure [34]. In contrast, obesity was
strongly associated with higher prevalence of all components
of the MetS including hypertension [32]. In agreement,
our ﬁndings demonstrated signiﬁcant stepwise increases
in the presence of central obesity, arterial hypertension,
raised triglycerides, and raised fasting plasma glucose with
increasing BMI category.
Inﬂammation within the adipose tissue has profound
adverse eﬀects on insulin signaling pathways [35]. In vitro
studies demonstrated that chronic exposure to IL-6 induces
insulin resistance in skeletal muscle through induction of
JNK, SOCS-3, and protein tyrosine phosphatase 1B [36].
In addition, upregulation of both IL-6 and TNF-α impairs
biological eﬀects of insulin also in adipose tissue [9, 37]. In
normoxemic noncachectic patients with COPD, associations
between reduced insulin sensitivity and increased IL-6 con-
centrations in the systemic circulation have been previously
observed [3]. Our study extends this observation further
and suggests that adipose tissue inﬂammation reﬂected by
increasesinCD68andTNF-αexpressionsplaysanimportant
role in the whole-body insulin resistance in patients with
COPD.
Macrophages are a signiﬁcant source of proinﬂamma-
tory molecules in most tissues [16]. In the present study,
we observed relationships between high adiposity, insulin





Figure 1: Histomorphological picture of adipose tissue in a cachectic (a) and obese (b) patient with chronic obstructive pulmonary disease
(×200 magniﬁcation).
Table 4: Adipose tissue-relative expressions of interleukin 6, tumor necrosis factor-alpha and its receptor, CD68, CASP3, and Bax gene in
patients with COPD.
mRNA expression (ΔΔCt) Entire group Group P value
Cachectic Normal weight Overweight Obese
IL-6 3.1 (1.3–4.3) 0.9 (0.5–1.0) 2.4 (1.4–4.7) 3.8 (2.9–4.8)∗ 3.9 (3.1–4.9)∗ <.001
TNF-α 5.5 (4.2–7.1) 5.1 (3.4–6.0) 4.6 (3.3–6.0) 5.5 (5.2–6.4) 9.6 (6.1–10.2)∗†‡ .005
TNFRSF1A 9.7 (8.0–11.8) 8.1 (6.4–9.5) 9.7 (8.2–11.9) 9.8 (8.1–11.7) 11.3 (9.7–15.3) .011
CD68 9.9 (7.9–16.7) 5.3 (4.6–8.1) 9.5 (6.7–11.0) 11.7 (9.3–17.2)∗ 18.0 (11.2–23.5)∗† .011
CASP3 5.3 (4.7–6.7) 5.3 (4.9–6.0) 4.7 (3.9–7.8) 5.0 (4.4–6.9) 6.2 (5.7–6.7) .890
Bax 2.2 (0.4–8.6) 0.9 (0.3–2.8) 3.3 (0.6–10.1) 1.4 (0.4–4.6) 6.5 (0.3–9.5) .175
Adipocyte diameter (μm) 68.2 (59.0–77.0) 48.1 (37.7–63.0) 60.6 (57.7–65.2) 69.7 (65.9–78.7)∗ 77.0 (75.3–77.9)∗† <.001
∗P<. 05 versus cachectic group.
†P<. 05 versus normal-weight group.
‡P<. 05 versus overweight group.
Values are given as median (interquartile range).
Relative mRNA expression was calculated using comparative quantiﬁcation method (ΔΔCt).
IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; TNFRSF1A: tumor necrosis factor superfamily receptor 1A; CASP3: Caspase 3.
Table 5: Linear relationships between IL-6, TNF-α, and CD68 relative expressions in adipose tissue and insulin sensitivity, BMI, adipocyte
diameter, FEV1, arterial oxygen saturation, and serum inﬂammatory markers.
IL-6 (Log ΔΔCt) TNF-α (Log ΔΔCt) CD68 (Log ΔΔCt)
R value P value R value P value R value P value
M/I, mg·kg−1·min−1 ·μU−1·mL −0.716 <.001 −0.438 .003 −0.425 .004
BMI, kg·m−2 0.565 <.001 0.448 .003 0.445 .003
Adipocyte diameter, μm 0.593 <.001 0.347 .024 0.469 .002
FEV1, % pred 0.245 .108 0.055 .727 0.014 .929
PaO2, mmHg 0.224 .145 0.023 .882 0.015 .924
CASP3 mRNA expression, (ΔΔCt) 0.249 .107 0.172 .259 0.023 .902
Bax mRNA expression, (ΔΔCt) 0.232 .142 0.094 .560 0.120 .454
Serum TNF-α (Log pg·mL−1) −0.234 .131 −0.013 .934 0.178 .253
S e r u mI L - 6( L o gp g ·mL−1) 0.232 .139 0.271 .083 0.364 .018
hsCRP (Log mg·L−1#) 0.180 .247 0.220 .157 0.212 .171
PaO2:a r t e r i a lo x y g e np a r t i a lp r e s s u r e ;M/I: insulin sensitivity—glucose uptake to insulinemia ratio; BMI: body mass index; FEV1: forced expiratory volume
in 1 second; CASP3: caspase 3; TNF-α: tumor necrosis factor alpha; IL-6: interleukin-6; hsCRP: high sensitivity C-reactive protein.Mediators of Inﬂammation 7
cell surface receptor CD68. In addition, adipose tissue CD68
expressions were related to the expressions of TNF-α and
IL-6 suggesting that macrophages might play a central role
in the promotion of inﬂammation within the adipose tissue
of COPD patients. Importantly, in contrast to some investi-
gations implying that, within the adipose tissue, adipocytes
are both the main source and target of proinﬂammatory
signals, other recent studies indicate that macrophages
within the stromal vascular fraction produce most of the
proinﬂammatory molecules [38]. Indeed, Permana et al.
[39] demonstrated that TNF-α produced by adipose tissue
macrophages promotes the appearance of the adipocyte
“inﬂammatory” phenotype and is also related to insulin
resistance, thus suggesting that the cross-talk between adi-
pose tissue macrophages and adipocytes generates a vicious
circle of aggravating adipose tissue inﬂammation and insulin
resistance [40]. Exploration of the respective contribution of
the adipocyte versus stromovascular fraction to the overall
adipose tissue inﬂammatory pattern was beyond the scope of
the present study and requires further investigation.
Our results demonstrating increases in adipose tissue
inﬂammation in association with increased trunk fat mass in
obese COPD patients raise an intriguing question: might the
local cytokine production from adipocytes from/around the
lungs contribute to the inﬂammatory processes within the
lungs and potentially to lung function impairment? Inter-
estingly, greater expressions of leptin within the bronchial
submucosa were previously observed in COPD patients
compared to healthy controls, in association with greater
expression of activated T lymphocytes [41]. In addition, a
positiveassociationbetweensputumconcentrationsofleptin
and TNF-α in stable patients with COPD suggests a role of
adipocytes in regulating airway inﬂammation in COPD [42].
These investigations coupled by the results of the present
study suggest that it is worthwhile to explore the interactions
between the local adipose tissue inﬂammation and bronchial
inﬂammation in the future.
Cachexia has been identiﬁed as a signiﬁcant determinant
of mortality in COPD, independent of lung function,
smoking, and BMI [42, 43]. In malignant and nonmalig-
nant conditions including COPD, the main mechanisms
underlying the loss of muscle mass are a fall in protein
synthesis and increase in protein degradation, in association
with accelerated muscle cell death [11]. In contrast, little
is known regarding mechanisms underlying the loss of
adipose tissue mass [44]. Studies in adipocyte cell lines and
in animal models demonstrated that tissue inﬂammation
might represent an important contributing mechanism to
fat loss. Inﬂammatory cytokines such as TNF-α can reduce
fat depot size by several means: by increasing lipolysis and
decreasing lipoprotein lipase activity, by decreasing lipogenic
enzymes, by down-regulating the adipogenic diﬀerentiation
factors, and by increasing adipose tissue apoptosis [45].
To this end, we analyzed relationships between the fat cell
size and the expressions of inﬂammatory and proapoptotic
molecules in the present study. Contrary to our expectations,
adiposetissueexpressionsofproapoptoticandinﬂammatory
markers were not increased in cachectic patients, and
CD68 or TNF-α expressions were not related to those of
either proapoptotic CASP3 or Bax. Therefore, activation
of proapoptotic processes was unlikely to be responsible
for adipose tissue loss in our patients. Interestingly, similar
observations were reported recently in patients with cancer
cachexia. In the report by Warne [46], mRNA expressions
of IL-6 and other cytokine and leukocyte markers were not
altered in cachectic patients with cancer, and no major fat
cell death was present either. Of note, the small size of
adipocytes in patients with COPD observed in the present
study was similar to that observed in patients with cancer-
related cachexia [47]. Future studies are needed to assess the
likelyroleofincreasedlipolysisand/orreducedlipogenesisin
adipose tissue loss.
There are several limitations to this study. First, our anal-
yses are based on single measurements of insulin sensitivity
and the respective adipose tissue mRNA expressions, which
may not reﬂect these relationships over time. Therefore,
this study does not provide information about the time-
course relationship between metabolic derangements and
activation of proinﬂammatory gene expression in adipose
tissue. In addition, factors related to the translation of
the mRNA into a stable or active protein have not been
studied, and analyses on the relationships between the
mRNA expressions of adipokines and their actual protein
levels within the adipose tissue remain to be explored in the
future.Second,thepresentstudywasnotdesignedtoaddress
directly the question of the origin of systemic inﬂammation
in patients with COPD. Analysis of the adipose tissue
contribution to the overall systemic inﬂammatory pattern
requires measurements of arteriovenous diﬀerences in the
concentrationsofinﬂammatorymediators[48],anapproach
used previously by Fontana et al. [49]. Such approach
was beyond the scope of the present investigation. Third,
the limited number of patients studied in four respective
groups is a limitation of this study. However, compared
to cachectic and normal-weight COPD patients, those with
obesity had median values of adipose tissue expressions of
CD68 higher by 240% and 89%, and of TNF-α by 88%
and 109%, respectively. We therefore believe that our results
are robust to gain some understanding of adipose tissue
inﬂammation in cachectic and obese COPD patients. Also,
it has to be underlined that concomitant measurements
of body composition, insulin resistance, and adipose tissue
expressions of inﬂammatory cytokines within one group of
patients with COPD are unique in the pulmonary literature
and represent the strength of the study.
In summary, the present study demonstrated relation-
ships between obesity, adipose tissue inﬂammation reﬂected
by increased adipose tissue expressions of CD68 and TNF-
α, and insulin resistance in patients with COPD. Cachectic
patients remain insulin sensitive, with no adipose tis-
sue upregulation of inﬂammatory or proapoptotic mark-
ers. Future studies are needed to investigate the role of
impaired lipolysis, lipogenesis, and/or aging on adipose
tissue structure and function in such patients. From the
clinical perspective, the impact of excessive fat mass on the
overall cardiovascular risk and prognosis of patients with
COPD and possible implications for nonpharmacological
and pharmacological interventions need to be explored.8 Mediators of Inﬂammation
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